Canada’s Drug Agency | Drugs, Health Technologies and Systems.

tarlatamab

Details

Files
Generic Name:
tarlatamab
Project Status:
Active
Therapeutic Area:
Extensive stage small cell lung cancer
Manufacturer:
Amgen Canada Inc.
Call for patient/clinician input open:
Brand Name:
Imdelltra
Project Line:
Reimbursement Review
Project Number:
PC0351-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​For the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation/Report:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openJuly 03, 2024
Call for patient/clinician input closedAugust 23, 2024
Submission receivedAugust 14, 2024
Submission acceptedAugust 28, 2024
Review initiatedAugust 29, 2024
Draft CADTH review report(s) provided to sponsor for commentNovember 15, 2024
Deadline for sponsors commentsNovember 26, 2024
CDA-AMC review report(s) and responses to comments provided to sponsorDecember 19, 2024
Expert committee meeting (initial)January 08, 2025
Draft recommendation issued to sponsorJanuary 21, 2025
Draft recommendation posted for stakeholder feedbackJanuary 30, 2025
End of feedback periodFebruary 13, 2025
Final recommendation issued to sponsor and drug plansFebruary 28, 2025
Final recommendation postedMarch 19, 2025
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)March 17, 2025
CDA-AMC review report(s) posted-

Files

Recommendation and Reasons View PDF
Patient and Clinician Group input View PDF
Last Updated : March 31, 2025